EFDID: 243096EFD: View Filing

Issuer: Trevi Therapeutics, Inc. (0001563880) - D/A

Accession: 0001563880-18-000002 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001563880
  • Entity Name:
    Trevi Therapeutics, Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    DELAWARE
  • Year of Inc:
    Over 5 years ago
  • Address:
    195 Church Street
    14th Floor
    New Haven, CT 06510
  • Persons:
    Related Persons 9
    Jennifer L. Good
    Executive Officer, Director
    Eran Nadav
    Director
    Annie Mitsak
    Director
    Ed Mathers
    Director
    Michael Heffernan
    Director
    Thomas R. Sciascia
    Executive Officer
    David Meeker
    Director
    Mette Kirstine Agger
    Director
    Chris Seiter
    Executive Officer
EDGAR: Offering Information
  • Accession Date:
    09/05/2018
  • First Sale Date:
    07/14/2017
  • Offering Amount:
    $61,906,460
  • Amount Sold:
    $51,906,460
  • Amount Remaining:
    $10,000,000
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity
EFD: Current State Notices

No State Notices found in EFD

EDGAR: Sales Compensation Recipient Information

There were no Sales Compensation Recipient Information associated with this Accession Number.

EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Trevi Therapeutics, Inc./s/ Jennifer L. GoodJennifer L. GoodPresident and Chief Executive Officer2018-09-05
Related EDGAR Submissions
Type Edgar Date EFD: Accession
D/A Sep. 05, 2018 243096: 0001563880-18-000002 Trevi Therapeutics, Inc.
Offer Amount: $61,906,460
Amount Sold: $51,906,460
Remaining: $10,000,000
D Jul. 24, 2017 243096: 0001563880-17-000001 Trevi Therapeutics, Inc.
Offer Amount: $66,656,460
Amount Sold: $41,148,460
Remaining: $25,508,000